Navigation Links
'EuroVacc 02' HIV Vaccine Trial Begins

ped within the network European Vaccine Effort against HIV/AIDS. NYVAC-HIV-C (a vaccine candidate based on poxvirus) was manufactured by sanofi pasteur - the vaccine division of Sanofi-Aventis - and has already been evaluated in a phase I study (EuroVacc 01) at the same clinical centres in Lausanne and London. The completed phase I study showed that the NYVAC-HIV-C is safe and immunogenic. The DNA-HIV-C vaccine was developed by Professors Hans Wolf and Ralf Wagner at the University of Regensburg based on a representative Chinese subtype C isolate CN54 jointly developed with Professor Yiming Shao from the CDC Beijing. The plasmid was constructed in collaboration with Geneart GmbH - a biotech company in Regensburg Germany, and the vaccine was manufactured by Cobra Biomanufacturing Plc.

About EuroVacc

The European Vaccine Effort against HIV/AIDS network, funded by the European Union under the 5th Framework Programme, involves 21 leading research laboratories as well as pharmaceutical companies and biotech companies in France, Germany, Italy, the Netherlands, Spain, Sweden, Switzerland and the United Kingdom. The goal of this network is to develop safe and effective preventive vaccines against HIV/AIDS. This group has been working together for more than five years, and has developed a pipeline of potential vaccines.

The EuroVacc Foundation, a non profit organization, was created in 2002 as an evolution of the network. The EuroVacc Foundation aims at facilitating European collaboration in vaccine development, coordinating European efforts and raising funds for fundamental and clinical research so as to accelerate the development of a safe and effective vaccine against HIV infection. The Foundation also promotes educational and training programmes relevant to vaccine development worldwide.

###

Notes:

Contrary to classical vaccine boosters, one strategy being developed for a preventive HIV vaccine comprises two
'"/>

Source:Imperial College London


Page: 1 2 3

Related biology news :

1. FDA Approves Human Hookworm Vaccine for Phase I Safety Trials
2. Live Recombinant Adenovirus Vaccine Technique Explored
3. Gene Vaccine Protects Mice Against Development Of Her2/neu Breast Cancer
4. NIAID Initiates Trial of Experimental Avian Flu Vaccine
5. Study Models Impact Of Anthrax Vaccine
6. New Insights Into HIV Immunity Suggest Alternative Approach to Vaccines
7. Pathogen-Mimicking Vaccine As Strategy For Cancer Therapy
8. Active Vaccine Prevents Mice From Developing Prion Disease
9. New Vaccine To Be Used For First Time In Polio Outbreak Response
10. Boosting The BCG Vaccine To Beat Tuberculosis
11. Visceral Leishmaniasis: Successful Vaccine Trial In Dogs
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: EuroVacc HIV Vaccine Trial Begins

(Date:6/30/2015)... HATFIELD, Pa. , June 30, 2015 ... joined the company as CEO to help further develop ... a wealth of partnering experience, having spent much of ... companies including Therakine, Amgen, Baxter Bioscience, and Johnson & ... a focus on Technology and Biotech Corporate Finance. He ...
(Date:6/26/2015)... Utah , June 26, 2015 ATL Technology, ... and devices with specialties in single use solutions, headquartered in ... of MedConx, Inc. (a California corporation ... and San Jose, Costa Rica ). ... Costa Rica with ATL Technology,s existing facility ...
(Date:6/25/2015)... SALT LAKE CITY , June 25, 2015 /PRNewswire/ ... the first steps toward a healthier, happier life. That,s ... app is designed to do. The cutting-edge, portable health ... and offers real-life solutions to help improve your lifestyle ... Sellers Association awards dinner and gala Wednesday night, USANA,s ...
Breaking Biology News(10 mins):Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2@USANAinc's Personalized Nutrition Program Wins Industry Innovation Award 2
... powerful class of antioxidants could one day be a potent ... antioxidants called synthetic triterpenoids blocked development of Parkinson,s in an ... days, said Dr. Bobby Thomas, neuroscientist at the Medical College ... of the study in the journal Antioxidants & Redox ...
... Award for Innovative Excellence, the Society,s highest award. ... Fulwyler, the inventor of the electrostatic cell sorter, and ... Dr. Terstappen received his Ph.D. in Applied Physics from ... pioneering cytometry research at Becton Dickinson. In 1994, ...
... July 23, 2012 Scientists at Joslin Diabetes ... (GLP-1), a gut hormone, protects against kidney disease, and ... findings, which are reported today online by Diabetes, may ... harness the actions of GLP-1 to prevent the harmful ...
Cached Biology News:Powerful class of antioxidants may be potent Parkinson's treatment 2The International Society for Advancement of Cytometry presented its 2012 awards at CYTO 2012 2The International Society for Advancement of Cytometry presented its 2012 awards at CYTO 2012 3Joslin researchers gain new understanding of diabetes and kidney disease 2Joslin researchers gain new understanding of diabetes and kidney disease 3
(Date:7/27/2015)... 27, 2015   Inocucor Technologies Inc ., ... accelerators for farmers, has received a notice of ... for its patent application to protect Inocucor consortia ... and enhance yields on farms and in greenhouses. ... live IN-M1 microbial consortium and its fermentation byproducts, ...
(Date:7/27/2015)... ... July 27, 2015 , ... ... sales network Monday. The venture will bring the world’s most efficient gas dissolution ... state-of-the-art equipment and technologies to both the industrial and municipal markets. With offices ...
(Date:7/27/2015)... July 27, 2015 The Brain ... winners of its annual Klerman and Freedman Prizes, ... who have been supported by NARSAD Young Investigator ... pursue innovative ideas in neurobiological and psychosocial research, ... for the early detection, treatment, prevention and cure ...
(Date:7/27/2015)... WESTBROOK, Maine , July 27, 2015 ... that more than 8,000 clinics have submitted over 100,000 ... SDMA, testing in just the first 10 days since ... Chronic kidney disease (CKD) is a leading cause of ... from the submitted specimens are consistent with generally accepted ...
Breaking Biology Technology:Inocucor Technologies Receives Groundbreaking U.S. Patent for Proprietary Biological Processes that Stimulate Plant Growth 2Inocucor Technologies Receives Groundbreaking U.S. Patent for Proprietary Biological Processes that Stimulate Plant Growth 3BlueInGreen Brings Water Treatment Technology to Florida 2Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 2Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 3Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 4Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 5Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 6Over 100,000 Pets Tested with New IDEXX SDMA Kidney Function Test Since Product Launch on July 13 2Over 100,000 Pets Tested with New IDEXX SDMA Kidney Function Test Since Product Launch on July 13 3Over 100,000 Pets Tested with New IDEXX SDMA Kidney Function Test Since Product Launch on July 13 4Over 100,000 Pets Tested with New IDEXX SDMA Kidney Function Test Since Product Launch on July 13 5
... combats an,alarming rise in chronic diseases, the Pharmaceutical ... new report on the next,generation of medicines in ... The report found that America,s pharmaceutical research ... - are,testing a record 633 new biotech medicines., ...
... and CHICAGO, Sept. 24 Omeros Corporation, a,Seattle-based ... million debt facility with BlueCrest Capital Finance. The ... by Omeros at closing and the,right, subject to ... $15,million. Other terms were not disclosed., "This ...
... specialty biopharmaceutical company,announces that at its Annual General Meeting today, all resolutions,contained in the notice of meeting ... ... Against Withheld** 1. To ... Emmens as a Director ...
Cached Biology Technology:New Report on 633 Biotechnology Medicines Under Development Released in Michigan 2New Report on 633 Biotechnology Medicines Under Development Released in Michigan 3Omeros and BlueCrest Announce $20 Million Debt Facility 2Results of the Annual General Meeting Held on September 24, 2008 2Results of the Annual General Meeting Held on September 24, 2008 3
Request Info...
... , Maintenance 112 days/each , ... Immunizations/Boost injections x5 /each , ... , Production bleed (25 ml blood =12 ml ... ml blood (~50 ml serum) x1 each , ...
... 500 g protein in 200 l ... whole cell lysate; Abelson transformed macrophage cells, ... blotting positive control, should be ... should be minimized, sample vial ...
muscle actin (HUC1-1)...
Biology Products: